Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 262 entries
Sorted by: Best Match Show Resources per page
Osimertinib as first-line therapy in advanced NSCLC: a profile of its use.

Drugs & therapy perspectives : for rational drug selection and use

Scott LJ.
PMID: 30631243
Drugs Ther Perspect. 2018;34(8):351-357. doi: 10.1007/s40267-018-0536-9. Epub 2018 Jul 06.

Osimertinib (Tagrisso

Cite
Scott LJ. Osimertinib as first-line therapy in advanced NSCLC: a profile of its use. Drugs Ther Perspect. 2018;34(8):351-357doi: 10.1007/s40267-018-0536-9.
Scott, L. J. (2018). Osimertinib as first-line therapy in advanced NSCLC: a profile of its use. Drugs & therapy perspectives : for rational drug selection and use, 34(8), 351-357. https://doi.org/10.1007/s40267-018-0536-9
Scott, Lesley J. "Osimertinib as first-line therapy in advanced NSCLC: a profile of its use." Drugs & therapy perspectives : for rational drug selection and use vol. 34,8 (2018): 351-357. doi: https://doi.org/10.1007/s40267-018-0536-9
Scott LJ. Osimertinib as first-line therapy in advanced NSCLC: a profile of its use. Drugs Ther Perspect. 2018;34(8):351-357. doi: 10.1007/s40267-018-0536-9. Epub 2018 Jul 06. PMID: 30631243; PMCID: PMC6300577.
Copy Download .nbib Format: NLM
Serum Vascular Endothelial Growth Factor Levels in the IVAN Trial; Relationships with Drug, Dosing, and Systemic Serious Adverse Events.

Ophthalmology. Retina

Rogers CA, Scott LJ, Reeves BC, Downes S, Lotery AJ, Dick AD, Chakravarthy U.
PMID: 30555977
Ophthalmol Retina. 2018 Feb;2(2):118-127. doi: 10.1016/j.oret.2017.05.015.

PURPOSE: To describe serum vascular endothelial growth factor (sVEGF) in patients with neovascular age-related macular degeneration (nAMD) receiving anti-VEGF agents and associations between sVEGF and systemic serious adverse events (SSAEs).DESIGN: Exploratory analyses of a randomized controlled trial that enrolled...

Cite
Rogers CA, Scott LJ, Reeves BC, et al. Serum Vascular Endothelial Growth Factor Levels in the IVAN Trial; Relationships with Drug, Dosing, and Systemic Serious Adverse Events. Ophthalmol Retina. 2018;2(2):118-127doi: 10.1016/j.oret.2017.05.015.
Rogers, C. A., Scott, L. J., Reeves, B. C., Downes, S., Lotery, A. J., Dick, A. D., & Chakravarthy, U. (2018). Serum Vascular Endothelial Growth Factor Levels in the IVAN Trial; Relationships with Drug, Dosing, and Systemic Serious Adverse Events. Ophthalmology. Retina, 2(2), 118-127. https://doi.org/10.1016/j.oret.2017.05.015
Rogers, Chris A, et al. "Serum Vascular Endothelial Growth Factor Levels in the IVAN Trial; Relationships with Drug, Dosing, and Systemic Serious Adverse Events." Ophthalmology. Retina vol. 2,2 (2018): 118-127. doi: https://doi.org/10.1016/j.oret.2017.05.015
Rogers CA, Scott LJ, Reeves BC, Downes S, Lotery AJ, Dick AD, Chakravarthy U. Serum Vascular Endothelial Growth Factor Levels in the IVAN Trial; Relationships with Drug, Dosing, and Systemic Serious Adverse Events. Ophthalmol Retina. 2018 Feb;2(2):118-127. doi: 10.1016/j.oret.2017.05.015. PMID: 30555977; PMCID: PMC6278944.
Copy Download .nbib Format: NLM
A bacterial index to estimate lake trophic level: National scale validation.

The Science of the total environment

Pearman JK, Wood SA, Vandergoes MJ, Atalah J, Waters S, Adamson J, Thomson-Laing G, Thompson L, Howarth JD, Hamilton DP, Pochon X, Biessy L, Brasell KA, Dahl J, Ellison R, Fitzsimons SJ, Gard H, Gerrard T, Gregersen R, Holloway M, Li X, Kelly DJ, Martin R, McFarlane K, McKay NP, Moody A, Moy CM, Naeher S, Newnham R, Parai R, Picard M, Puddick J, Rees ABH, Reyes L, Schallenberg M, Shepherd C, Short J, Simon KS, Steiner K, Šunde C, Terezow M, Tibby J.
PMID: 34942258
Sci Total Environ. 2021 Dec 21;812:152385. doi: 10.1016/j.scitotenv.2021.152385. Epub 2021 Dec 21.

Lakes and their catchments have been subjected to centuries to millennia of exploitation by humans. Efficient monitoring methods are required to promote proactive protection and management. Traditional monitoring is time consuming and expensive, which limits the number of lakes...

Cite
Pearman JK, Wood SA, Vandergoes MJ, et al. A bacterial index to estimate lake trophic level: National scale validation. Sci Total Environ. 2021;812:152385doi: 10.1016/j.scitotenv.2021.152385.
Pearman, J. K., Wood, S. A., Vandergoes, M. J., Atalah, J., Waters, S., Adamson, J., Thomson-Laing, G., Thompson, L., Howarth, J. D., Hamilton, D. P., Pochon, X., Biessy, L., Brasell, K. A., Dahl, J., Ellison, R., Fitzsimons, S. J., Gard, H., Gerrard, T., Gregersen, R., Holloway, M., Li, X., Kelly, D. J., Martin, R., McFarlane, K., McKay, N. P., Moody, A., Moy, C. M., Naeher, S., Newnham, R., Parai, R., Picard, M., Puddick, J., Rees, A. B. H., Reyes, L., Schallenberg, M., Shepherd, C., Short, J., Simon, K. S., Steiner, K., Šunde, C., Terezow, M., & Tibby, J. (2021). A bacterial index to estimate lake trophic level: National scale validation. The Science of the total environment, 812152385. https://doi.org/10.1016/j.scitotenv.2021.152385
Pearman, John K, et al. "A bacterial index to estimate lake trophic level: National scale validation." The Science of the total environment vol. 812 (2021): 152385. doi: https://doi.org/10.1016/j.scitotenv.2021.152385
Pearman JK, Wood SA, Vandergoes MJ, Atalah J, Waters S, Adamson J, Thomson-Laing G, Thompson L, Howarth JD, Hamilton DP, Pochon X, Biessy L, Brasell KA, Dahl J, Ellison R, Fitzsimons SJ, Gard H, Gerrard T, Gregersen R, Holloway M, Li X, Kelly DJ, Martin R, McFarlane K, McKay NP, Moody A, Moy CM, Naeher S, Newnham R, Parai R, Picard M, Puddick J, Rees ABH, Reyes L, Schallenberg M, Shepherd C, Short J, Simon KS, Steiner K, Šunde C, Terezow M, Tibby J. A bacterial index to estimate lake trophic level: National scale validation. Sci Total Environ. 2021 Dec 21;812:152385. doi: 10.1016/j.scitotenv.2021.152385. Epub 2021 Dec 21. PMID: 34942258.
Copy Download .nbib Format: NLM
A bacterial index to estimate lake trophic level: National scale validation.

The Science of the total environment

Pearman JK, Wood SA, Vandergoes MJ, Atalah J, Waters S, Adamson J, Thomson-Laing G, Thompson L, Howarth JD, Hamilton DP, Pochon X, Biessy L, Brasell KA, Dahl J, Ellison R, Fitzsimons SJ, Gard H, Gerrard T, Gregersen R, Holloway M, Li X, Kelly DJ, Martin R, McFarlane K, McKay NP, Moody A, Moy CM, Naeher S, Newnham R, Parai R, Picard M, Puddick J, Rees ABH, Reyes L, Schallenberg M, Shepherd C, Short J, Simon KS, Steiner K, Šunde C, Terezow M, Tibby J.
PMID: 34942258
Sci Total Environ. 2021 Dec 21;812:152385. doi: 10.1016/j.scitotenv.2021.152385. Epub 2021 Dec 21.

Lakes and their catchments have been subjected to centuries to millennia of exploitation by humans. Efficient monitoring methods are required to promote proactive protection and management. Traditional monitoring is time consuming and expensive, which limits the number of lakes...

Cite
Pearman JK, Wood SA, Vandergoes MJ, et al. A bacterial index to estimate lake trophic level: National scale validation. Sci Total Environ. 2021;812:152385doi: 10.1016/j.scitotenv.2021.152385.
Pearman, J. K., Wood, S. A., Vandergoes, M. J., Atalah, J., Waters, S., Adamson, J., Thomson-Laing, G., Thompson, L., Howarth, J. D., Hamilton, D. P., Pochon, X., Biessy, L., Brasell, K. A., Dahl, J., Ellison, R., Fitzsimons, S. J., Gard, H., Gerrard, T., Gregersen, R., Holloway, M., Li, X., Kelly, D. J., Martin, R., McFarlane, K., McKay, N. P., Moody, A., Moy, C. M., Naeher, S., Newnham, R., Parai, R., Picard, M., Puddick, J., Rees, A. B. H., Reyes, L., Schallenberg, M., Shepherd, C., Short, J., Simon, K. S., Steiner, K., Šunde, C., Terezow, M., & Tibby, J. (2021). A bacterial index to estimate lake trophic level: National scale validation. The Science of the total environment, 812152385. https://doi.org/10.1016/j.scitotenv.2021.152385
Pearman, John K, et al. "A bacterial index to estimate lake trophic level: National scale validation." The Science of the total environment vol. 812 (2021): 152385. doi: https://doi.org/10.1016/j.scitotenv.2021.152385
Pearman JK, Wood SA, Vandergoes MJ, Atalah J, Waters S, Adamson J, Thomson-Laing G, Thompson L, Howarth JD, Hamilton DP, Pochon X, Biessy L, Brasell KA, Dahl J, Ellison R, Fitzsimons SJ, Gard H, Gerrard T, Gregersen R, Holloway M, Li X, Kelly DJ, Martin R, McFarlane K, McKay NP, Moody A, Moy CM, Naeher S, Newnham R, Parai R, Picard M, Puddick J, Rees ABH, Reyes L, Schallenberg M, Shepherd C, Short J, Simon KS, Steiner K, Šunde C, Terezow M, Tibby J. A bacterial index to estimate lake trophic level: National scale validation. Sci Total Environ. 2021 Dec 21;812:152385. doi: 10.1016/j.scitotenv.2021.152385. Epub 2021 Dec 21. PMID: 34942258.
Copy Download .nbib Format: NLM
Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms.

Leukemia

Short NJ, Kantarjian H, Jabbour E.
PMID: 34172894
Leukemia. 2021 Nov;35(11):3044-3058. doi: 10.1038/s41375-021-01277-3. Epub 2021 Jun 25.

In the past decade, the available treatments for patients with acute lymphoblastic leukemia (ALL) have rapidly expanded, in parallel with an increased understanding of the genomic features that impact the disease biology and clinical outcomes. With the development of...

Cite
Short NJ, Kantarjian H, Jabbour E. Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms. Leukemia. 2021;35(11):3044-3058doi: 10.1038/s41375-021-01277-3.
Short, N. J., Kantarjian, H., & Jabbour, E. (2021). Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms. Leukemia, 35(11), 3044-3058. https://doi.org/10.1038/s41375-021-01277-3
Short, Nicholas J, et al. "Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms." Leukemia vol. 35,11 (2021): 3044-3058. doi: https://doi.org/10.1038/s41375-021-01277-3
Short NJ, Kantarjian H, Jabbour E. Optimizing the treatment of acute lymphoblastic leukemia in younger and older adults: new drugs and evolving paradigms. Leukemia. 2021 Nov;35(11):3044-3058. doi: 10.1038/s41375-021-01277-3. Epub 2021 Jun 25. PMID: 34172894.
Copy Download .nbib Format: NLM
Dietary Intake and Representativeness of a Diverse College-Attending Population Compared with an Age-Matched US Population.

Nutrients

Rana ZH, Frankenfeld CL, de Jonge L, Kennedy EJ, Bertoldo J, Short JL, Cheskin LJ.
PMID: 34836066
Nutrients. 2021 Oct 26;13(11). doi: 10.3390/nu13113810.

Young adults typically gain more dietary autonomy as they start college, though this can also present nutritional challenges; however, research on the generalizability of their dietary intake data is scarce. To address this representativeness concern, we compared food and...

Cite
Rana ZH, Frankenfeld CL, de Jonge L, et al. Dietary Intake and Representativeness of a Diverse College-Attending Population Compared with an Age-Matched US Population. Nutrients. 2021;13(11)doi: 10.3390/nu13113810.
Rana, Z. H., Frankenfeld, C. L., de Jonge, L., Kennedy, E. J., Bertoldo, J., Short, J. L., & Cheskin, L. J. (2021). Dietary Intake and Representativeness of a Diverse College-Attending Population Compared with an Age-Matched US Population. Nutrients, 13(11), . https://doi.org/10.3390/nu13113810
Rana, Ziaul H, et al. "Dietary Intake and Representativeness of a Diverse College-Attending Population Compared with an Age-Matched US Population." Nutrients vol. 13,11 (2021). doi: https://doi.org/10.3390/nu13113810
Rana ZH, Frankenfeld CL, de Jonge L, Kennedy EJ, Bertoldo J, Short JL, Cheskin LJ. Dietary Intake and Representativeness of a Diverse College-Attending Population Compared with an Age-Matched US Population. Nutrients. 2021 Oct 26;13(11). doi: 10.3390/nu13113810. PMID: 34836066; PMCID: PMC8621081.
Copy Download .nbib Format: NLM
A bacterial index to estimate lake trophic level: National scale validation.

The Science of the total environment

Pearman JK, Wood SA, Vandergoes MJ, Atalah J, Waters S, Adamson J, Thomson-Laing G, Thompson L, Howarth JD, Hamilton DP, Pochon X, Biessy L, Brasell KA, Dahl J, Ellison R, Fitzsimons SJ, Gard H, Gerrard T, Gregersen R, Holloway M, Li X, Kelly DJ, Martin R, McFarlane K, McKay NP, Moody A, Moy CM, Naeher S, Newnham R, Parai R, Picard M, Puddick J, Rees ABH, Reyes L, Schallenberg M, Shepherd C, Short J, Simon KS, Steiner K, Šunde C, Terezow M, Tibby J.
PMID: 34942258
Sci Total Environ. 2021 Dec 21;812:152385. doi: 10.1016/j.scitotenv.2021.152385. Epub 2021 Dec 21.

Lakes and their catchments have been subjected to centuries to millennia of exploitation by humans. Efficient monitoring methods are required to promote proactive protection and management. Traditional monitoring is time consuming and expensive, which limits the number of lakes...

Cite
Pearman JK, Wood SA, Vandergoes MJ, et al. A bacterial index to estimate lake trophic level: National scale validation. Sci Total Environ. 2021;812:152385doi: 10.1016/j.scitotenv.2021.152385.
Pearman, J. K., Wood, S. A., Vandergoes, M. J., Atalah, J., Waters, S., Adamson, J., Thomson-Laing, G., Thompson, L., Howarth, J. D., Hamilton, D. P., Pochon, X., Biessy, L., Brasell, K. A., Dahl, J., Ellison, R., Fitzsimons, S. J., Gard, H., Gerrard, T., Gregersen, R., Holloway, M., Li, X., Kelly, D. J., Martin, R., McFarlane, K., McKay, N. P., Moody, A., Moy, C. M., Naeher, S., Newnham, R., Parai, R., Picard, M., Puddick, J., Rees, A. B. H., Reyes, L., Schallenberg, M., Shepherd, C., Short, J., Simon, K. S., Steiner, K., Šunde, C., Terezow, M., & Tibby, J. (2021). A bacterial index to estimate lake trophic level: National scale validation. The Science of the total environment, 812152385. https://doi.org/10.1016/j.scitotenv.2021.152385
Pearman, John K, et al. "A bacterial index to estimate lake trophic level: National scale validation." The Science of the total environment vol. 812 (2021): 152385. doi: https://doi.org/10.1016/j.scitotenv.2021.152385
Pearman JK, Wood SA, Vandergoes MJ, Atalah J, Waters S, Adamson J, Thomson-Laing G, Thompson L, Howarth JD, Hamilton DP, Pochon X, Biessy L, Brasell KA, Dahl J, Ellison R, Fitzsimons SJ, Gard H, Gerrard T, Gregersen R, Holloway M, Li X, Kelly DJ, Martin R, McFarlane K, McKay NP, Moody A, Moy CM, Naeher S, Newnham R, Parai R, Picard M, Puddick J, Rees ABH, Reyes L, Schallenberg M, Shepherd C, Short J, Simon KS, Steiner K, Šunde C, Terezow M, Tibby J. A bacterial index to estimate lake trophic level: National scale validation. Sci Total Environ. 2021 Dec 21;812:152385. doi: 10.1016/j.scitotenv.2021.152385. Epub 2021 Dec 21. PMID: 34942258.
Copy Download .nbib Format: NLM
Harnessing the benefits of available targeted therapies in acute myeloid leukaemia.

The Lancet. Haematology

Kantarjian H, Short NJ, DiNardo C, Stein EM, Daver N, Perl AE, Wang ES, Wei A, Tallman M.
PMID: 34687602
Lancet Haematol. 2021 Dec;8(12):e922-e933. doi: 10.1016/S2352-3026(21)00270-2. Epub 2021 Oct 20.

Research has resulted in regulatory approval of nine agents for acute myeloid leukaemia indications by the US Food and Drug Administration since 2017: the Bcl-2 inhibitor, venetoclax; two FLT3 inhibitors, midostaurin and gilteritinib; two IDH inhibitors, ivosidenib (IDH1 inhibitor)...

Cite
Kantarjian H, Short NJ, DiNardo C, et al. Harnessing the benefits of available targeted therapies in acute myeloid leukaemia. Lancet Haematol. 2021;8(12):e922-e933doi: 10.1016/S2352-3026(21)00270-2.
Kantarjian, H., Short, N. J., DiNardo, C., Stein, E. M., Daver, N., Perl, A. E., Wang, E. S., Wei, A., & Tallman, M. (2021). Harnessing the benefits of available targeted therapies in acute myeloid leukaemia. The Lancet. Haematology, 8(12), e922-e933. https://doi.org/10.1016/S2352-3026(21)00270-2
Kantarjian, Hagop, et al. "Harnessing the benefits of available targeted therapies in acute myeloid leukaemia." The Lancet. Haematology vol. 8,12 (2021): e922-e933. doi: https://doi.org/10.1016/S2352-3026(21)00270-2
Kantarjian H, Short NJ, DiNardo C, Stein EM, Daver N, Perl AE, Wang ES, Wei A, Tallman M. Harnessing the benefits of available targeted therapies in acute myeloid leukaemia. Lancet Haematol. 2021 Dec;8(12):e922-e933. doi: 10.1016/S2352-3026(21)00270-2. Epub 2021 Oct 20. PMID: 34687602.
Copy Download .nbib Format: NLM
A cross-species assay demonstrates that reward responsiveness is enduringly impacted by adverse, unpredictable early-life experiences.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology

Kangas BD, Short AK, Luc OT, Stern HS, Baram TZ, Pizzagalli DA.
PMID: 34921225
Neuropsychopharmacology. 2021 Dec 17; doi: 10.1038/s41386-021-01250-9. Epub 2021 Dec 17.

Exposure to early-life adversity (ELA) is associated with several neuropsychiatric conditions, including major depressive disorder, yet causality is difficult to establish in humans. Recent work in rodents has implicated impaired reward circuit signaling in anhedonic-like behavior after ELA exposure....

Cite
Kangas BD, Short AK, Luc OT, et al. A cross-species assay demonstrates that reward responsiveness is enduringly impacted by adverse, unpredictable early-life experiences. Neuropsychopharmacology. 2021;doi: 10.1038/s41386-021-01250-9.
Kangas, B. D., Short, A. K., Luc, O. T., Stern, H. S., Baram, T. Z., & Pizzagalli, D. A. (2021). A cross-species assay demonstrates that reward responsiveness is enduringly impacted by adverse, unpredictable early-life experiences. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, . https://doi.org/10.1038/s41386-021-01250-9
Kangas, Brian D, et al. "A cross-species assay demonstrates that reward responsiveness is enduringly impacted by adverse, unpredictable early-life experiences." Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology vol. (2021). doi: https://doi.org/10.1038/s41386-021-01250-9
Kangas BD, Short AK, Luc OT, Stern HS, Baram TZ, Pizzagalli DA. A cross-species assay demonstrates that reward responsiveness is enduringly impacted by adverse, unpredictable early-life experiences. Neuropsychopharmacology. 2021 Dec 17; doi: 10.1038/s41386-021-01250-9. Epub 2021 Dec 17. PMID: 34921225.
Copy Download .nbib Format: NLM
Emergence of .

Frontiers in oncology

Alotaibi AS, Yilmaz M, Loghavi S, DiNardo C, Borthakur G, Kadia TM, Thakral B, Pemmaraju N, Issa GC, Konopleva M, Short NJ, Patel K, Tang G, Ravandi F, Daver N.
PMID: 33194747
Front Oncol. 2020 Oct 20;10:588876. doi: 10.3389/fonc.2020.588876. eCollection 2020.

Despite the promising result with FLT3 inhibitors in AML, the emergence of resistance poses a significant challenge, leading to a shorter response duration and inferior survival. This is frequently driven by on-target or parallel prosurvival mutations. The emergence of

Cite
Alotaibi AS, Yilmaz M, Loghavi S, et al. Emergence of . Front Oncol. 2020;10:588876doi: 10.3389/fonc.2020.588876.
Alotaibi, A. S., Yilmaz, M., Loghavi, S., DiNardo, C., Borthakur, G., Kadia, T. M., Thakral, B., Pemmaraju, N., Issa, G. C., Konopleva, M., Short, N. J., Patel, K., Tang, G., Ravandi, F., & Daver, N. (2020). Emergence of . Frontiers in oncology, 10588876. https://doi.org/10.3389/fonc.2020.588876
Alotaibi, Ahmad S, et al. "Emergence of ." Frontiers in oncology vol. 10 (2020): 588876. doi: https://doi.org/10.3389/fonc.2020.588876
Alotaibi AS, Yilmaz M, Loghavi S, DiNardo C, Borthakur G, Kadia TM, Thakral B, Pemmaraju N, Issa GC, Konopleva M, Short NJ, Patel K, Tang G, Ravandi F, Daver N. Emergence of . Front Oncol. 2020 Oct 20;10:588876. doi: 10.3389/fonc.2020.588876. eCollection 2020. PMID: 33194747; PMCID: PMC7606916.
Copy Download .nbib Format: NLM
Correction to: The help for people with money, employment or housing problems (HOPE) intervention: pilot randomised trial with mixed methods feasibility research.

Pilot and feasibility studies

Barnes MC, Haase AM, Scott LJ, Linton MJ, Bard AM, Donovan JL, Davies R, Dursley S, Williams S, Elliott D, Potokar J, Kapur N, Hawton K, O'Connor RC, Hollingworth W, Metcalfe C, Gunnell D.
PMID: 30505459
Pilot Feasibility Stud. 2018 Nov 28;4:177. doi: 10.1186/s40814-018-0374-5. eCollection 2018.

[This corrects the article DOI: 10.1186/s40814-018-0365-6.].

Cite
Barnes MC, Haase AM, Scott LJ, et al. Correction to: The help for people with money, employment or housing problems (HOPE) intervention: pilot randomised trial with mixed methods feasibility research. Pilot Feasibility Stud. 2018;4:177doi: 10.1186/s40814-018-0374-5.
Barnes, M. C., Haase, A. M., Scott, L. J., Linton, M. J., Bard, A. M., Donovan, J. L., Davies, R., Dursley, S., Williams, S., Elliott, D., Potokar, J., Kapur, N., Hawton, K., O'Connor, R. C., Hollingworth, W., Metcalfe, C., & Gunnell, D. (2018). Correction to: The help for people with money, employment or housing problems (HOPE) intervention: pilot randomised trial with mixed methods feasibility research. Pilot and feasibility studies, 4177. https://doi.org/10.1186/s40814-018-0374-5
Barnes, M C, et al. "Correction to: The help for people with money, employment or housing problems (HOPE) intervention: pilot randomised trial with mixed methods feasibility research." Pilot and feasibility studies vol. 4 (2018): 177. doi: https://doi.org/10.1186/s40814-018-0374-5
Barnes MC, Haase AM, Scott LJ, Linton MJ, Bard AM, Donovan JL, Davies R, Dursley S, Williams S, Elliott D, Potokar J, Kapur N, Hawton K, O'Connor RC, Hollingworth W, Metcalfe C, Gunnell D. Correction to: The help for people with money, employment or housing problems (HOPE) intervention: pilot randomised trial with mixed methods feasibility research. Pilot Feasibility Stud. 2018 Nov 28;4:177. doi: 10.1186/s40814-018-0374-5. eCollection 2018. PMID: 30505459; PMCID: PMC6260749.
Copy Download .nbib Format: NLM
Evaluation and management of measurable residual disease in acute lymphoblastic leukemia.

Therapeutic advances in hematology

Abou Dalle I, Jabbour E, Short NJ.
PMID: 32215194
Ther Adv Hematol. 2020 Mar 06;11:2040620720910023. doi: 10.1177/2040620720910023. eCollection 2020.

With standard chemotherapy regimens for adults with acute lymphoblastic leukemia, approximately 90% of patients achieve complete remission. However, up to half of patients have persistent minimal/measurable residual disease (MRD) not recognized by routine microscopy, which constitutes the leading determinant...

Cite
Abou Dalle I, Jabbour E, Short NJ. Evaluation and management of measurable residual disease in acute lymphoblastic leukemia. Ther Adv Hematol. 2020;11:2040620720910023doi: 10.1177/2040620720910023.
Abou Dalle, I., Jabbour, E., & Short, N. J. (2020). Evaluation and management of measurable residual disease in acute lymphoblastic leukemia. Therapeutic advances in hematology, 112040620720910023. https://doi.org/10.1177/2040620720910023
Abou Dalle, Iman, et al. "Evaluation and management of measurable residual disease in acute lymphoblastic leukemia." Therapeutic advances in hematology vol. 11 (2020): 2040620720910023. doi: https://doi.org/10.1177/2040620720910023
Abou Dalle I, Jabbour E, Short NJ. Evaluation and management of measurable residual disease in acute lymphoblastic leukemia. Ther Adv Hematol. 2020 Mar 06;11:2040620720910023. doi: 10.1177/2040620720910023. eCollection 2020. PMID: 32215194; PMCID: PMC7065280.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 262 entries